Emerging Microbes and Infections (Jan 2021)

The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China

  • Hongchao Jiang,
  • Zhen Zhang,
  • Qing Rao,
  • Xiaodan Wang,
  • Meifen Wang,
  • Tingyi Du,
  • Jiaolian Tang,
  • Shuying Long,
  • Juan Zhang,
  • Jia Luo,
  • Yue Pan,
  • Junying Chen,
  • Jing Ma,
  • Xiaomei Liu,
  • Mao Fan,
  • Tiesong Zhang,
  • Qiangming Sun

DOI
https://doi.org/10.1080/22221751.2021.1899772
Journal volume & issue
Vol. 10, no. 1
pp. 619 – 628

Abstract

Read online

Enterovirus A71 (EV-A71) inactivated vaccines have been widely inoculated among children in Kunming City after it was approved. However, there was a large-scale outbreak of Enteroviruses (EVs) infection in Kunming, 2018. The epidemiological characteristics of HFMD and EVs were analysed during 2008–2018, which are before and three years after EV-A71 vaccine starting to use. The changes in infection spectrum were also investigated, especially for severe HFMD in 2018. The incidence of EV-A71 decreased dramatically after the EV-A71 vaccine starting use. The proportion of non-CV-A16/EV-A71 EVs positive patients raised to 77.17–85.82%, while, EV-A71 and CV-A16 only accounted for 3.41–7.24% and 6.94–19.42% in 2017 and 2018, respectively. CV-A6 was the most important causative agent in all clinical symptoms (severe HFMD, HFMD, Herpangina and fever), accounting from 42.13% to 62.33%. EV-A71 only account for 0.36–2.05%. In severe HFMD, CV-A6 (62.33%), CV-A10 (11.64%), and CV-A16 (10.96%) were the major causative agent in 2018. EV-A71 inactivated vaccine has a good protective effect against EV-A71 and induced EVs infection spectrum changefully. EV-A71 vaccine has no or insignificant cross-protection effect on CV-A6, CV-A10, and CV-A16. Herein, developing 4-valent combined vaccines is urgently needed.

Keywords